Geode Capital Management LLC Grows Stock Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Geode Capital Management LLC grew its holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 13.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,188,120 shares of the company's stock after acquiring an additional 144,256 shares during the period. Geode Capital Management LLC owned about 2.23% of Zevra Therapeutics worth $9,912,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in ZVRA. AIGH Capital Management LLC purchased a new stake in Zevra Therapeutics during the fourth quarter worth $6,577,000. JPMorgan Chase & Co. grew its position in shares of Zevra Therapeutics by 50.5% in the fourth quarter. JPMorgan Chase & Co. now owns 27,490 shares of the company's stock valued at $229,000 after purchasing an additional 9,225 shares in the last quarter. EntryPoint Capital LLC purchased a new stake in shares of Zevra Therapeutics in the fourth quarter valued at approximately $221,000. Corebridge Financial Inc. grew its position in shares of Zevra Therapeutics by 16.9% in the fourth quarter. Corebridge Financial Inc. now owns 26,294 shares of the company's stock valued at $219,000 after purchasing an additional 3,801 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Zevra Therapeutics by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 2,824,212 shares of the company's stock valued at $23,554,000 after purchasing an additional 68,151 shares in the last quarter. 35.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. HC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Guggenheim upped their price objective on Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, March 13th. Finally, Canaccord Genuity Group upped their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a report on Thursday, March 13th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Zevra Therapeutics presently has a consensus rating of "Buy" and an average target price of $22.29.

Zevra Therapeutics Stock Up 0.4 %

Shares of Zevra Therapeutics stock traded up $0.03 during trading hours on Tuesday, reaching $7.23. 334,199 shares of the company were exchanged, compared to its average volume of 611,571. Zevra Therapeutics, Inc. has a 1 year low of $4.20 and a 1 year high of $9.76. The stock's fifty day moving average is $7.49 and its 200 day moving average is $8.11. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The firm has a market cap of $395.33 million, a PE ratio of -3.67 and a beta of 1.94.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The company had revenue of $12.00 million for the quarter, compared to analysts' expectations of $8.93 million. As a group, equities research analysts forecast that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Insider Activity at Zevra Therapeutics

In other Zevra Therapeutics news, Director John B. Bode bought 10,000 shares of the company's stock in a transaction that occurred on Wednesday, March 19th. The shares were purchased at an average price of $7.96 per share, with a total value of $79,600.00. Following the completion of the acquisition, the director now directly owns 40,000 shares of the company's stock, valued at $318,400. This represents a 33.33 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO R. Laduane Clifton sold 11,000 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $86,460.00. Following the completion of the transaction, the chief financial officer now directly owns 51,361 shares in the company, valued at $403,697.46. This trade represents a 17.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 85,773 shares of company stock valued at $674,176 over the last quarter. 2.40% of the stock is owned by insiders.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.